Enanta Pharmaceuticals investor relations material

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. It focuses on developing its late-stage product candidates that target non-structural protein 3 protease (NS3/4A) of hepatitis C virus (HCV) and compounds targeting NS5A of HCV. The company's lead clinical candidate, paritaprevir, is developed in collaboration with AbbVie in a combination therapy regimen for the treatment of genotype 1 HCV; EDP-522 as an NS5A inhibitor for the treatment of chronic hepatitis B virus; and EDP-239 as an HCV NS3 protease inhibitor.